Phenylbutazone bioavailability from an enteric-coated formulation (Butacote) has been studied in normal volunteers following ingestion of a single 200 mg dose with water, aluminium hydroxide and magnesium trisili-cate. No significant alteration in bioavailability of phenylbutazone from Butacote was noted in the presence of the antacids.
Get full access to this article
View all access options for this article.
References
1.
BurnsJ J, RoseR K, ChenkinT H, GoldmanA, SchulertA & BrodieB B (1953) The physiological disposition of phenylbutazone (Butazolidin) in man and a method for its estimation in biological material. Journal of Pharmacology and Experimental Therapeutics, 109, 346
2.
DaviesD S & ThorgeirssonS S (1971) Individual differences in the plasma half-lives of lipid soluble drugs in man. Acta Pharmacologica et Toxicologica, 29, Supp 1-4, 181
3.
DielerleW (1975) Comparison of pharmacokinetic and metabolic properties of phenylbutazone and oxyphenbutazone. Ciba-Geigy Report PC No 20/1975
4.
FeldmanS & CarlstedtB C (1974) Effect of antacid on absorption of enteric-coated aspirin. Journal of the American Medical Association, 227, 660
5.
GibaldiM & PerrierD (1975) ‘Pharmacokinetics’. Ed SwarbrickJ.Marcel Dekker, Inc., New York, 150
6.
LeesonL J, ShinalE C, LukasG, ZakS B & WeinerM (1975) The objective and timing of drug disposition studies. Appendix IV. Phenylbutazone formulations: in vitro dissolution and in vivo performance. Drug Metabolism Reviews4, (2), 277
7.
PantioM, StrandmanD & TikkanenR (1968) Absorption of phenylbutazone from enteric-coated and regular tablets. Acta Rheumalologica Scandinavica, 14, 113
Strickland-HodgeB, ThomasT R, GouldW A & HaslockI (1976) The effects of antacids on enteric-coated salicylate preparations. Rheumatology and Rehabilitation, 15, 148
10.
SwinseowTD V (1976) Statistics at square one. XVII–Some non-parametric tests. British Medical Journal, 3, 632
11.
WagnerJ G (1967) Method of estimating relative absorption of a drug in a series of clinical studies in which blood levels are measured after single and/or multiple doses. Journal of Pharmaceutical Sciences, 56, 652
12.
WagnerJ G (1973) G15 137: Binding to human serum proteins in vitro. Report B 36/1973
